Depression and immunity: A role for T cells?

Abstract

Much attention has been paid to the potential role of the immune system in the pathophysiology of major depression in humans. While activation of innate immune responses currently dominates the research landscape, early studies in depressed patients demonstrating impairment in acquired immune responses, in particular T cell responses, may warrant further consideration. Intriguing data suggest that activated T cells may play an important neuroprotective role in the context of both stress and inflammation. For example, generation of autoreactive T cells through immunization with central nervous system (CNS) specific antigens has been shown to reverse stress-induced decreases in hippocampal neurogenesis as well as depressive-like behavior in rodents. In addition, trafficking of T cells to the brain following stress, in part related to glucocorticoids, has been found to reduce stress-induced anxiety-like behavior. Data indicate that T regulatory cells may also play a role in depression through downregulation of chronic inflammatory responses. Based on the notion that T cells may subserve neuroprotective and anti-inflammatory functions during stress and inflammation, impaired T cell function may directly contribute to the development of depression. Indeed, increased sensitivity to apoptosis as well as reduced responsiveness to glucocorticoids, may not only decrease the availability of T cells in depressed patients, but also may reduce their capacity to traffic to the brain in response to relevant neuroendocrine or immune stimuli. Further elucidation of T cell pathology may lead to new insights into immune system contributions to depression. Moreover, enhancement of T cell function may represent an alternative strategy to treat depression.

Introduction

Having spent much of my research career studying the impact of an activated immune system on depression and vice versa, it has been heartening for me to see the tremendous progress that has been made in terms of understanding not only how the immune system interacts with pathophysiologic pathways relevant to depression, but also how new therapies targeting the immune system might enrich the strategies which can be used to manage this devastating disease. It is strikingly clear that depression is one of the most disabling of chronic illnesses (Moussavi et al., 2007), leading to death by suicide in as many as 15% of patients (Sudak, 2005). To compound the problem, almost a third of depressed patients are unable to respond to or tolerate conventional antidepressant medications (Greden, 2001, Rush, 2007), and therefore the need for novel therapeutic approaches is especially timely. The urgency of non-response and evidence that treatment resistant depressed patients may be especially likely to exhibit immune system activation only heightens the interest in further developing approaches that involve the immune system to treat depression (Lanquillon et al., 2000, Miller et al., 2009).

Much of our recent focus has been on the role of the activated innate immune response and inflammation in neuronal integrity and neuropsychiatric disorders including depression (Dantzer et al., 2008, Miller et al., 2009). Indeed, each year, the number of presentations on these topics at the annual meeting of the Psychoneuroimmunology Research Society (PNIRS) has steadily increased. However, at the PNIRS meeting this year, we were reminded that acquired immune responses, in particular T cell responses, also contribute to stress- and depression-related vulnerabilities and resilience. Indeed, data was presented and discussed that T cells may play an important neuroprotective role in the context of stress and inflammation (Lewitus and Schwartz, 2009, Lewitus et al., 2009, Rook and Lowry, 2008). This more active role of T cells in nervous system function is in stark contrast to the theoretical notions of years past when T cells were viewed largely as innocent victims of the ravages of depression on the body, ultimately contributing to increased vulnerability in the context of a host of illnesses including infectious diseases and cancer. In my Presidential Address, I would like to take this opportunity to review where we have come in our understanding of the immune system and depression and revisit our early notions of the relevance of T cells in depression, especially in the light of new data on the impact of T cells on the brain and behavior. More specifically, I would like to elaborate the hypothesis that decreases in the number and function of relevant T cell subsets may directly to contribute to the development and maintenance of depression, and restoration and/or enhancement of relevant T cell functions may represent an interesting and novel approach to the treatment of this disorder.